Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.

Abstract

Samples from a total of 367 NSCLC patients were tested, to different time to tumour progression were found in erlotinib and gefitinib treated patients, overal survival was better in erlotinib group.

Keywords

• EGFR and KRAS mutations
• NSCLC patients